Boston Scientific Corp. stock (US10117L1017): FMR LLC cuts major stake in Q1 2026

Boston Scientific Corp. (BSX), a leading medical device company, saw a notable development in its shareholder base as FMR LLC disclosed a significant reduction in its stake. On March 31, 2026, FMR LLC cut its holdings by 21,551,258 shares, according to GuruFocus as of May 2026. This move comes amid ongoing market volatility in the healthcare sector, with BSX shares down 3.33% over the past week and 12.32% over the last month as reported in competitive analyses.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Boston Scientific Corp.: core business model

Boston Scientific Corp. develops, manufactures, and markets medical devices for minimally invasive procedures worldwide. The company focuses on specialties like cardiology, endoscopy, and urology, serving hospitals and clinics with innovative technologies. Its business model emphasizes research and development, with significant investments in new product launches to maintain market leadership.

Key to its operations is a global footprint, with the US as its primary revenue source, making it highly relevant for American investors tracking medtech exposure. The firm's portfolio includes stents, pacemakers, and ablation systems, addressing chronic conditions prevalent in aging populations.

Main revenue and product drivers for Boston Scientific Corp.

Cardiovascular interventions represent the largest revenue segment, driven by products like the Synergy XD stent and Watchman left atrial appendage closure device. Endoscopy contributes through systems for gastrointestinal procedures, while urology grows via pelvic health solutions. In its most recent full-year report, net income reached $2.90 billion, underscoring robust profitability as of data published in 2026 competitive reviews.

Revenue growth stems from procedure volume increases in the US market, bolstered by favorable demographics and expanded indications for devices. The company reported strong performance relative to peers, with a price-to-book ratio of 3.08.

Industry trends and competitive position

The medical device sector faces tailwinds from rising demand for outpatient procedures and digital health integration. Boston Scientific Corp. holds a strong position against competitors like Medtronic and Abbott, differentiating through specialized franchises. Recent competitive data shows BSX outperforming in net income at $2.90B versus peer averages of $223.05M.

Why Boston Scientific Corp. matters for US investors

Listed on the NYSE, Boston Scientific Corp. offers US investors direct exposure to the $500+ billion medtech market, with over 50% of revenues from North America. Its innovation pipeline aligns with US healthcare spending trends, including Medicare expansions for device therapies.

Conclusion

The reduction in FMR LLC's stake highlights shifting institutional interest in Boston Scientific Corp., amid recent share price weakness. While the company maintains solid fundamentals in medtech, investors monitor competitive dynamics and sector trends. Ongoing product innovation positions it for long-term relevance in US healthcare.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.